Eli Lilly GLP-1 Strategy Boom and Revenue Shock
Can Eli Lilly’s GLP-1 boom keep powering the stock as regulation, lawsuits and ETF concentration risks close in? Maik Kemper Editor in Chief Conclusion The…
Eli Lilly Forecast Warning after HSBC’s bearish reset
Is the latest bearish Eli Lilly Forecast a rare buying opportunity or the start of a painful valuation reset in GLP-1 leaders? Maik Kemper Editor…
Novo Nordisk FDA warning: Safety shock and WHO funding pivot
Can the Novo Nordisk FDA warning derail the GLP-1 boom just as a new WHO partnership reshapes the company’s global image? How serious is the…
Hims & Hers Novo Nordisk deal sparks 44% premarket surge
Can the new Hims & Hers Novo Nordisk deal really turn an 80% stock collapse into a long-term GLP-1 comeback story? How big is the…
Eli Lilly Investment -$37.70: Rally Warning for Bulls
Can the latest Eli Lilly Investment wave in GLP-1 plants and AI supercomputing still justify a trillion-dollar style valuation? How does the Eli Lilly Investment…